Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 4-amino-N-2-pyrimidinyl-benzene-2,3,5,6-d4-sulfonamide
- Correlated keywords
- NSC 35600 NSC35600 deuterated deuterium GCMS LCMS Sulfanilylaminopyrimidine A 306 A306 Adiazin Adiazine Coco-Diazine Cremodiazine Debenal Deltazina Di-Azo-Mul Diazin Diazolone Diazovit Diazyl Eskadiazine Honey diazine Lipo Levazine Liquadiazine Microsulfon N1-2-Pyrimidinylsulfanilamide Pyrimidylsulfanilamide Neazine Piridisir Pirimal Pyrimal RP 2616 RP2616 SDA SN 112 SN112 Sanodiazine Spofadrizine Sterazine Sulfadiazin Sulfadiazina Reig Jofre Sulfapirimidin Sulfapyrimidine Sulfazin Sulfazine Sulfolex Sulphadiazine E Theradiazine Mycobacterium Neisseria Actinobacillus Salmonella Pasteurella Streptococcus Toxoplasma Pneumocystis
- Product Overview:
Sulfadiazine-d4 is intended for use as an internal standard for the quantification of sulfadiazine (Item No. 23719) by GC- or LC-MS. Sulfadiazine is a sulfonamide antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria.{38582,36439,36440,36441} It inhibits dihydropteroate synthase (DHPS), which converts a pteridine and 4-aminobenzoic acid (PABA; Item No. 18659) to dihydropteroate, an intermediate in folate biosynthesis.{38582} Sulfadiazine inhibits recombinant P. carinii DHPS (IC50 = 0.19 ?M). It is active against clinical isolates of M. tuberculosis (MIC90 = 10 mg/L) and of N. meningitidis (MICs = 5-2,000 mg/L).{36439,36440} Sulfadiazine is also active against A. pleuropneumoniae, S. choleraesuis, S. typhimurium, P. multocida, S. equi, and S. suis (MIC90s = 16473).{36441} In vivo, sulfadiazine (40 mg/kg per day) increases survival in a mouse model of lethal T. gondii infection when administered in combination with pyrimethamine (Item No. 16472).{36442} Formulations containing sulfadiazine have been used in the treatment of rheumatic fever and various infections, and, in a dual treatment with pyrimethamine, to treat toxoplasmosis.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.